TBK1 and amyotrophic lateral sclerosis: Importantly, we found that treatment with 50 nM gefitinib (low dose) significantly reduced neuronal damage in a TBK1-deficient cellular model of ALS, indicating that pharmacological modulation of OPTN in mitophagy might be a new strategy for the treatment of ALS and possibly other neurodegenerative disorders.